Why Are EnGene Holdings Shares Trading Lower Friday?
Why Are EnGene Holdings Shares Trading Lower Friday?
EnGene Holdings Inc. (NASDAQ:ENGN) shares are trading lower Friday after the company, reported its financial results for the second quarter.
EnGene Holdings Inc.（納斯達克：ENGN）股價週五下跌，該公司發佈了其第二季度財務業績報告。
What To Know: EnGene Holdings announced a net loss of $15.0 million, or $0.38 per share, compared to a loss of $6.5 million, or $9.30 per share, for the same period in 2023, according to Benzinga Pro. This increase in net loss is primarily due to higher operating expenses, which rose from $4.7 million to $17.3 million year-over-year, driven by increased research and development costs and administrative expenses as the company scales its operations.
了解一下：根據Benzinga Pro的數據，EnGene Holdings宣佈淨虧損爲1500萬美元，每股虧損爲0.38美元，而2023年同期虧損650萬美元，每股虧損爲9.3美元。淨虧損增加主要是由於營業費用增加，從470萬美元增至1730萬美元，這是由於公司在擴大業務規模方面增加了研發成本和行政支出。
What Else: In addition to financial updates, EnGene highlighted strategic developments, including the planned expansion of its pivotal LEGEND study to include high-risk, BCG-unresponsive papillary-only NMIBC patients. Interim data from this cohort is expected by the end of September 2024, with a Biologics License Application (BLA) for EG-70 projected for mid-2026.
此外，除了財務業績更新外，EnGene還突出了其戰略發展，包括計劃將有高風險、BCG無響應性的僅泡狀NMIBC患者加入其重要的LEGEND研究。這組人的中期數據預計將在2024年9月底前公佈，EG-70的生物製品許可申請（BLA）預計將於2026年中期提交。
Related Link: enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update
相關鏈接：enGene報告2024年第二季度財務業績並提供業務更新
EnGene has also made key leadership hires, including Dr. Raj Pruthi as SVP of Urologic Oncology and Clinical Development, to bolster their clinical efforts. Despite the financial challenges, enGene remains focused on advancing EG-70 and exploring additional applications within bladder cancer.
EnGene還聘請了關鍵的領導人，包括Raj Pruthi博士擔任泌尿腫瘤和臨床開發高級副總裁，以加強他們的臨床工作。儘管面臨着財務挑戰，但EnGene仍專注於推進EG-70並探索膀胱癌的其他應用。
Price Action: EnGene Holdings shares were down by 11.6% at $8.84 according to Benzinga Pro.
價格行動：根據Benzinga Pro的數據，EnGene Holdings股票下跌11.6％，報8.84美元。
Photo Via Shutterstock.
照片來自shutterstock。
譯文內容由第三人軟體翻譯。